CA3111569A1 - Anti-trem-2 agonist antibodies - Google Patents
Anti-trem-2 agonist antibodies Download PDFInfo
- Publication number
- CA3111569A1 CA3111569A1 CA3111569A CA3111569A CA3111569A1 CA 3111569 A1 CA3111569 A1 CA 3111569A1 CA 3111569 A CA3111569 A CA 3111569A CA 3111569 A CA3111569 A CA 3111569A CA 3111569 A1 CA3111569 A1 CA 3111569A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729458P | 2018-09-11 | 2018-09-11 | |
| US62/729,458 | 2018-09-11 | ||
| PCT/US2019/050575 WO2020055975A1 (en) | 2018-09-11 | 2019-09-11 | Anti-trem-2 agonist antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3111569A1 true CA3111569A1 (en) | 2020-03-19 |
Family
ID=69777153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3111569A Pending CA3111569A1 (en) | 2018-09-11 | 2019-09-11 | Anti-trem-2 agonist antibodies |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12145988B2 (https=) |
| EP (1) | EP3849598A4 (https=) |
| JP (1) | JP2022500081A (https=) |
| KR (1) | KR20210057113A (https=) |
| CN (1) | CN113164572A (https=) |
| AU (1) | AU2019339452A1 (https=) |
| BR (1) | BR112021004316A2 (https=) |
| CA (1) | CA3111569A1 (https=) |
| IL (1) | IL281201A (https=) |
| MX (1) | MX2021002616A (https=) |
| SG (1) | SG11202102162RA (https=) |
| WO (1) | WO2020055975A1 (https=) |
| ZA (1) | ZA202101537B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2023192282A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| CA3254085A1 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women's Hospital, Inc. | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024160736A1 (en) * | 2023-01-30 | 2024-08-08 | Isar Bioscience Gmbh | Human anti-trem2 antibody for treating neurodegenerative disorders |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US20150140672A1 (en) | 2011-12-19 | 2015-05-21 | Washington University | Methods for detecting amyloid beta amyloidosis |
| AU2012359020B2 (en) | 2011-12-19 | 2017-04-13 | The Washington University | Methods for diagnosing Alzheimer's disease |
| EP2923209A4 (en) | 2012-11-20 | 2016-04-27 | Univ Washington | METHOD FOR THE DIAGNOSIS OF DISEASES BY ANALYSIS OF AMYLOID BETA ENRICHMENT KINETICS |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2016064895A1 (en) * | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CN109641961A (zh) * | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
-
2019
- 2019-09-11 CA CA3111569A patent/CA3111569A1/en active Pending
- 2019-09-11 WO PCT/US2019/050575 patent/WO2020055975A1/en not_active Ceased
- 2019-09-11 JP JP2021538178A patent/JP2022500081A/ja active Pending
- 2019-09-11 SG SG11202102162RA patent/SG11202102162RA/en unknown
- 2019-09-11 EP EP19860614.7A patent/EP3849598A4/en not_active Withdrawn
- 2019-09-11 BR BR112021004316A patent/BR112021004316A2/pt not_active Application Discontinuation
- 2019-09-11 AU AU2019339452A patent/AU2019339452A1/en not_active Abandoned
- 2019-09-11 KR KR1020217010551A patent/KR20210057113A/ko not_active Withdrawn
- 2019-09-11 MX MX2021002616A patent/MX2021002616A/es unknown
- 2019-09-11 CN CN201980074318.5A patent/CN113164572A/zh active Pending
- 2019-09-11 US US17/275,092 patent/US12145988B2/en active Active
-
2021
- 2021-03-02 IL IL281201A patent/IL281201A/en unknown
- 2021-03-05 ZA ZA2021/01537A patent/ZA202101537B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004316A2 (pt) | 2021-11-03 |
| JP2022500081A (ja) | 2022-01-04 |
| MX2021002616A (es) | 2021-05-12 |
| ZA202101537B (en) | 2022-07-27 |
| US12145988B2 (en) | 2024-11-19 |
| EP3849598A4 (en) | 2022-07-06 |
| CN113164572A (zh) | 2021-07-23 |
| IL281201A (en) | 2021-04-29 |
| AU2019339452A1 (en) | 2021-03-25 |
| EP3849598A1 (en) | 2021-07-21 |
| KR20210057113A (ko) | 2021-05-20 |
| US20210284727A1 (en) | 2021-09-16 |
| SG11202102162RA (en) | 2021-04-29 |
| WO2020055975A1 (en) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12145988B2 (en) | Anti-TREM-2 agonist antibodies | |
| US12540175B2 (en) | Anti-ApoE antibodies | |
| JP6900500B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| AU2009245354C1 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| US20150315267A1 (en) | A method of reducing brain amyloid plaques using anti-ab antibodies | |
| US20210324110A1 (en) | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides | |
| CA3135181A1 (en) | Fusion constructs and uses thereof | |
| CN120858110A (zh) | 用抗Aβ抗体治疗神经病症的方法 | |
| US20250163136A1 (en) | Anti-transthyretin (ttr) binding proteins and uses thereof | |
| JP2026504928A (ja) | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250829 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 |